NCT02477969 - Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin | Biotech Hunter

Enrollment

587

Participants

Timeline

Start Date

February 27, 2014

Primary Completion Date

June 22, 2016

Study Completion Date

June 30, 2017

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

PEX168(100µg)

PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks

DRUG

PEX168(200µg)

PEX168,Subcutaneous injection,once a week. continued for 52 weeks

DRUG

Placebo

0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.

DRUG

Metformin

0.5mg,oral,tid.

Trial Locations (1)

Shanghai sixth People's Hospital, Shanghai